Platelet-Rich Plasma in Interstitial Cystitis/Bladder Pain Syndrome: A Systematic Review and Meta-Analysis
Hajebrahimi S., Tahmasbi F., Jahantabi E., Hosseinpour G., Taneja R., Salehi-Pourmehr H.
Meta-analysis with a reported sample of 426, published in Adv Pharm Bull (2025) — summary generated from the PubMed abstract.
Relatively higher-quality human studies compared with other topics in this database, e.g. multiple RCTs or systematic reviews. This does not mean it is standard or approved care.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Meta-analysis
- Journal
- Adv Pharm Bull (2025)
- Reported sample size
- 426
- Source database
- Europe PMC
- PMID
- 41403738
- PMCID
- PMC12703394
- DOI
- 10.34172/apb.025.45444
Abstract (original English)
Purpose This systematic review aims to critically evaluate the safety and efficacy of PRP therapy in managing interstitial cystitis/bladder pain syndrome (IC/BPS). Methods Two researchers independently searched related Databases and collected all studies from inception to December 5, 2023. Outcome indicators of symptom relief were pain scores self-assessment using the VAS system, IC symptoms using the O'Leary-Sant score (OSS), urinary frequency, nocturia, post-void residual (PVR), voided volume, and functional bladder capacity. Results Among 372 retrieved articles, 13 studies, including 426 patients, were included. The pain of patients decreased significantly after treatment with platelet-rich plasma (PRP) compared to the baseline values (MD: -1.93, 95% CI: -2.28, -1.58). All subgroup analyses revealed a decrease in VAS scores after PRP injection. IC symptoms using OSS, and ICSI decreased significantly after treatment. Conclusion PRP therapy as a new and successful course of treatment may be a novel therapeutic approach in IC/BPS cases. More study with the control arm is required to enhance treatment regimens for this difficult condition and to better understand the mechanisms of action of PRP in IC/BPS.
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
Evidence level
Relatively higher-quality human studies compared with other topics in this database, e.g. multiple RCTs or systematic reviews. This does not mean it is standard or approved care.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.